Pfizer, $14 billion down after its biotech bonanza buyout of Medivation in cash this week, still has money in the pot to buy AstraZeneca’s antibiotics unit.

A new deal from Novartis outlicenses its Phase II-ready, anti-PCSK9 antibody for a couple of inflammatory indications that include sepsis.

Microcap Tokai has had a summer to forget, but its woes got worse this week as it announced that it will stop enrollment in one trial and ax another as its…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…

Partners Eli Lilly and AstraZeneca got a leap ahead in the BACE inhibitor race as they secure a fast-track designation from the FDA for Phase III candidate…

The privately owned Dublin, Ireland-based DS Biopharma has spun out a company from its ranks in order for it to focus specifically on scarring diseases, while…

Biotech Thar Pharmaceuticals is gunning for a $50 million IPO as it looks to launch its first pivotal trial in 2017 for an oral form of a marketed bone drug…

Move over Sanofi, your original $9.3 billion bid and even your second, sweetened offer has been blown out of the water by the $14 billion being put on the…